Diabetes continues to pose a significant global health burden, affecting millions of individuals worldwide. The International Diabetes Federation estimated that there were 537 million people with diabetes mellitus (DM) globally in 2021 and projects this disease to increase to 643 million by 2030 and 783 million by 2045 [1]. Caring for patients with diabetes requires addressing many issues, particularly cardiovascular and renal, besides glycemic control. Recent guidelines for the management of cardiovascular disease (CVD) in diabetes and diabetes management in chronic kidney disease (CKD) are available from specialty experts [2, 3]. The American Association of Clinical Endocrinology has also published a recent consensus statement on the comprehensive management of type 2 DM (T2DM) [4]. The prevalence of diabetes is rising and so, effective, evidence-based strategies for diagnosis, monitoring, and management are needed. The 2025 American Diabetes Association (ADA)’s Standards of Medical Care in Diabetes, a hefty 343-page document, serve as a critical resource for clinicians, laboratorians, and policymakers, offering recommendations that are updated annually to reflect the most current scientific advancements.

The 2025 ADA guidelines introduce transformative updates that address gaps in the 2024 standards. This commentary highlights these key changes, focusing on continuous glucose monitoring (CGM) for broader populations, advancements in pharmacological therapies, resistance training, and expanded recommendations for lifestyle and dietary interventions. Additionally, the guidelines also address emerging topics such as the implications of recreational cannabis use in diabetes management and the enhanced screening for presymptomatic T1DM.

Though the 2024 ADA Standards of Care recommended autoantibody screening for T1DM and emphasized its role in identifying high-risk individuals, it has not been widely adopted in clinical practice [5]. The 2025 update expands on this and underscores the value of antibody-based screening for presymptomatic T1DM in individuals with a family history of the disease. This addition reflects advances in understanding T1DM as a progressive autoimmune condition that can be detected early through specific markers. Screening for autoantibodies to insulin, glutamic acid decarboxylase (GAD), islet antigen 2 (IA-2), or zinc transporter 8 (ZnT8) allows for the identification of high-risk individuals at high risk prior to the onset of hyperglycemia [6]. Early detection can facilitate timely intervention, participation in prevention trials, and preparedness for disease onset, ultimately improving long-term outcomes and management strategies. Besides, teplizumab, a humanized CD3-directed monoclonal antibody, has been approved as a treatment to delay the progression of T1DM [7].

In the 2024 ADA Standards of Care in Diabetes, significant emphasis was placed on using HbA1c levels as a key diagnostic tool for diabetes, supported by its established correlation with average blood glucose levels and ease of testing [5]. However, the 2025 guidelines expand on this by providing a detailed comparison that addresses critical considerations in the utilization of HbA1c versus plasma glucose for diabetes diagnosis [6]. The comparison between glucose testing and HbA1c highlights notable differences in within-patient variability and standardization. Glucose levels show high variability due to acute influences such as food intake, stress, and diurnal changes, making it less reliable for consistent monitoring [8, 9]. In contrast, HbA1c demonstrates low within-person variability, providing a stable measure of average glucose over time. Additionally, while glucose assays lack universal standardization and can vary by sample type and processing, HbA1c testing is well-standardized, ensuring greater reliability across different laboratories [10]. This shift in focus demonstrates the ADA’s efforts to enhance the accuracy and equity of diabetes diagnostics, integrating these nuances to better tailor diagnostic practices to individual patient needs.

The 2025 ADA Standards of Care emphasize the integral role of diabetes self-management education and support (DSMES) in improving diabetes outcomes across the lifespan. A significant update is the increased focus on personalized, culturally tailored DSMES programs that address social determinants of health and ensure equitable access. The guidelines underscore the need for ongoing education at critical life stages or care transitions, such as diagnosis, changes in treatment regimens, and development of complications. Digital platforms and virtual DSMES programs are now highlighted as essential tools to expand accessibility and engagement, particularly for underserved populations [19].

The 2025 ADA Standards of Care introduce several updates to the 2024 guidelines on technological integration in diabetes management [25]. CGM is now strongly recommended for a broader population, including individuals with T2DM not on insulin, thus expanding its use beyond intensive insulin regimens [25, 26]. CGMs are now integrated with automated insulin delivery systems. Based on feedback from the CGM insulin delivery is adjusted. Fully automated systems (end to end), designated as closed-loop systems, are receiving increased focus for their ability to personalize insulin delivery and reflect new evidence of improved glycemic outcomes [25, 27]. The guidelines also place greater emphasis on digital tools, such as mobile apps and virtual platforms, to enhance patient engagement and care accessibility [25].

The 2025 ADA Standards of Care integrate the latest findings from groundbreaking clinical trials, reflecting the evolving landscape of diabetes management. Research supporting early intervention with SGLT2 inhibitors highlights their effectiveness in slowing the progression of CKD, offering dual cardiovascular and renal protection [19, 28]. Additionally, evidence from trials like SELECT emphasizes the dual benefits of GLP-1 RAs for glycemic control and significant weight loss, addressing the dual burden of obesity and diabetes [17, 29]. These findings underscore the growing importance of tailoring therapies to prevent complications and improve outcomes.

Emerging areas of research also include the role of natriuretic peptides as biomarkers for early diagnosis and risk stratification, expanding diagnostic precision in high-risk populations [30]. Advances in diabetes technology, such as hybrid closed-loop systems and CGM, are further supported by studies demonstrating improvements in time-in-range and patient-reported outcomes [25, 27, 31]. The guidelines also highlight disparities in access to care, urging research into equitable distribution of novel therapies and technologies to maximize their global impact. This evidence-driven approach ensures that diabetes care remains patient-centered and aligned with the latest scientific advancements.

In response to global concerns, the 2025 ADA Standards of Care emphasize reducing global health disparities in diabetes care, particularly in low-resource settings [32]. The guidelines call for improving access to essential treatments, including affordable medications, and expanding the availability of diabetes technologies such as CGM. They also highlight strategies like telemedicine and community-based diabetes education to reach underserved populations. Additionally, the guidelines advocate for collaborative efforts to address cost barriers and ensure equitable healthcare delivery, aiming to bridge gaps and enhance outcomes globally [33].

The 2025 guidelines reflect a comprehensive update informed by recent clinical trials and emerging trends in diabetes management. The shift towards individualized care, integration of technology, and holistic lifestyle recommendations aligns with the evolving needs of patients and healthcare providers. It is not our intent to be comprehensive in our coverage of the 2025 ADA guidelines on standards of medical care in diabetes. We highly commend the reading of the guidelines in its entirety to all involved in diabetes care.

Table 1 summarizes the key revisions and recommendations that we have gleaned from the 2025 ADA guidelines.

These 2025 ADA updates reinforce the commitment to evidence-based practices and patient-centered care in DM. The broader adoption of innovative therapies and technologies, alongside a deeper focus on sustainability and equity, marks a significant step forward in improving diabetes outcomes globally.